RVMD stock news · Revolution Medicines, Inc.
Get alerts for RVMD
Follow Revolution Medicines, Inc. (RVMD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RVMDTango Therapeutics shares important news about its drug trial results.
Good for RVMDThe results include tumor shrinkage among patients treated with Revolution Medicines' daraxonrasib in combination with Tango's drug. The patient groups were small and side effects occurred, so the findings are encouraging but do not yet prove the treatment helps patients broadly.
Revolution Medicines starts a big study for a new lung cancer treatment.
Good for RVMDRevolution Medicines has begun a late-stage lung cancer study, building on early signs of tumor response. The treatment still needs to prove it helps patients.
BMF Capital questions SELLAS Life Sciences' nearly $3 billion valuation, labeling it as the biotech industry's "costliest gamble.
NeutralTicker is listed but not materially discussed in the source; no directional evidence is provided.
FDA grants approval to Revolution Medicines for its groundbreaking pancreatic cancer treatment.
Good for RVMDRevolution Medicines Inc. has received FDA approval for its drug Rasonque, the first targeted therapy from a new class of RAS inhibitors for metastatic pancreatic adenocarcinoma, based on successful Phase 3 trial results.